Damora Therapeutics, Inc. SEC filings DMRA
Damora Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to Jan 16, 2020. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 20, 2026 (material agreement, change to shareholder rights, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 12, 2026 | — |
| POSASR | Filing | Aug 10, 2026 | — |
| 8-A12B/A | Filing | Aug 10, 2026 | — |
| EFFECT | Filing | Dec 23, 2025 | — |
| CORRESP | Letter to the SEC | Dec 22, 2025 | — |
| D | Filing | Nov 21, 2025 | — |
| EFFECT | Filing | Nov 12, 2021 | — |
| CORRESP | Letter to the SEC | Nov 10, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2021 | — |
| D | Filing | Nov 5, 2020 | — |
| EFFECT | Filing | Oct 28, 2020 | — |
| CERT | 8a cert | Oct 28, 2020 | — |
| CORRESP | Letter to the SEC | Oct 26, 2020 | — |
| 8-A12B | Form 8-a12b | Oct 23, 2020 | — |
| CORRESP | Letter to the SEC | Oct 23, 2020 | — |
| CORRESP | Letter to the SEC | Oct 23, 2020 | — |
| CORRESP | Letter to the SEC | Oct 20, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 7, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2020 | — |
| DRS | Filing | Sep 2, 2020 | — |
| D | Filing | Jan 16, 2020 | — |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1800315
- Former names
- Galecto, Inc. (until Mar 10, 2026); Galecto Inc. (until Oct 28, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.